Organic cation transporter preferentially expressed in hematopoietic cells and leukemias and uses thereof
US7723019B2 · kind B2 · utility
0Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2006 |
| Grant date | May 25, 2010 |
| Priority date | — |
| Expiry date | Dec 10, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A novel organic cation transporter (OCT) gene, OCT 6, and use thereof is described. The OCT6 gene is preferentially expressed in human hematopoietic tissues, including CD34+ cells and leukemia cells. Its narrow tissue distribution, substrate specificity, and close homology to other cell membrane transporters make OCT6 an attractive target for the treatment of myeloid diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.